Fortis Healthcare Ltd Q2 FY27 Earnings Call: Rs. 3,500 Cr Capex For 2,200-Bed Expansion, IHH Eyes Stake Above 50%

Fortis Healthcare Ltd held its Q2 FY27 earnings call on November 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Double-Digit Growth, Modest Margin Expansion, Soft PAT Conversion

• Consolidated revenue of Rs.2,735 Cr in Q2 FY 2026-2027 — up 17.3% YoY; hospital business revenue Rs.2,340 Cr (+18.6%) and diagnostics gross revenue Rs.448 Cr (+12.2% vs Rs.400 Cr in Q2 FY 2025-2026).
• Operating EBITDA (pre-ESOP) of Rs.663 Cr, +19.2% YoY — margin 24.2% vs 23.9% in Q2 FY 2025-2026; hospital EBITDA Rs.545 Cr (margin 23.3% vs 22.9%); diagnostics margin 26.2% vs 26.1%.
• PAT ex-exceptionals of Rs.317 Cr, up only 4% YoY (vs Rs.305 Cr) — profit growth lagged the ~19% EBITDA growth; ESOP expense reduced Q2 FY 2026-2027 reported EBITDA by ~1.5% of revenue.
• H1 FY 2026-2027 revenue of Rs.5,280 Cr (+17.4% YoY) — hospital Rs.4,527 Cr (+18.8%); diagnostics Rs.855 Cr (+11.2%); PAT ex-exceptionals Rs.581 Cr (+3.8% vs Rs.559 Cr in H1 FY 2025-2026).
• Occupancy at 72% (vs 71% YoY) — occupied beds 3,616 (+9%); ARPP Rs.2.1 lakh (+6.8%); IP volume grew ~13% YoY in Q2 FY 2026-2027.
• Net debt of Rs.2,188 Cr; net debt/EBITDA at 0.87x as of September 30, 2026, improved from 0.96x as of September 30, 2025.

Specialty Mix Strong; Agilus Growth Trails Listed Peers

• Key specialty revenue growth in Q2 FY 2026-2027 — orthopedics +30%, neurosciences +28%, renal sciences +27% YoY.
• Agilus processed 11.39 million tests in Q2 FY27 (+7.2%) — patient volumes +5.8% YoY and +9.9% QoQ; ~300 customer touch points added gross in the quarter (4,551 total as of September 30, 2026).
• Analyst flagged Agilus volume growth of ~5% and test growth of 6-7% trailing listed peers at 10-13% — CEO Vijendra Singh cited an improving mix (wellness contribution up to 15% from 12% earlier, B2C at 54%) and expects volume growth to improve from current levels.
• Diagnostics wellness revenue +28% and specialized testing +14% YoY in Q2 FY 2026-2027 — B2C:B2B mix at 54:46 (vs 52:48 in Q2 FY26); Agilus is deploying GenAccess systems for next-generation sequencing and molecular diagnostics.
• International revenue grew 12.4% YoY to Rs.190 Cr (~8% of revenues) — digital channel revenue grew 18.6% YoY, contributing 29.5% of hospital revenue.
• 15 hospital facilities delivered EBITDA margin above 20% in Q2 FY 2026-2027, contributing 84% of hospital revenues (vs 13 facilities / 76% in FY 2025-2026).

2,000-Bed Roadmap with 3-4 Year Visibility; Rs.3,500 Cr Committed Capex

• Management reaffirmed the 2,200-bed expansion chart with delivery timelines over the next 3-4 years; CFO Vivek Goel clarified the ~2,000-bed pipeline comprises completed acquisitions plus brownfield — essentially no greenfield beds, with the 400-bed Ashok Vihar trust-arrangement project counted over and above the 2,000.
• Phasing per CFO: ~500+ organic beds in FY 2026-2027 (including the 100-bed Sumana Bangalore acquisition); ~200 beds per year from brownfield in each of FY 2027-2028 and FY 2028-2029; a big jump expected in FY 2030 on completion of the Mohali and Shalimar Bagh brownfield expansions; balance operationalized in FY 2030-2031.
• Committed capex of roughly Rs.3,500 Cr spread over the next ~3-3.5 years, excluding inorganic opportunities; management stated capital is not a constraint — the constraint is getting the right opportunity at the right price.
• Management expects a similar number (~2,000 beds) to be added to the pipeline over the next two years and the total to be "much higher" over the next 3-4 years given continuous acquisitions and active greenfield scouting; greenfield beds expected ~3 years from now, with 1-2 projects of a different nature possibly adding beds over FY 2027-2028.
• Bangalore acquisition secured via direct negotiation for Rs.270 Cr (including land and building, plus stamp duty); a further 40-bed expansion and renovation to Fortis standards will cost another Rs.140-odd crore (period unspecified).
• Board-approved internal benchmarks — management generally does not pursue projects with IRR below 15% or payback above 8-10 years, though these metrics may be overridden for the larger strategic picture.
• Strategic M&A under evaluation in Mumbai, Kolkata and Hyderabad clusters — including build-to-suit sale and build-to-suit lease models, and a couple of opportunities in large tier-2 cities with large markets.

Bangalore Occupancy Lags; Punjab Capacity-Constrained; FMRI Awaits Approvals

• Goldman Sachs' Shyam Srinivasan flagged slower growth in Punjab and Mumbai despite ~19% headline growth in Q2 FY 2026-2027; CFO Vivek Goel attributed the Punjab slowdown to capacity constraints, with all cluster units running occupancy above 70% (some above 75%).
• Bangalore cluster occupancy at ~63%, below other regions — the Benagata Road hospital runs at ~58% occupancy (profitable despite this) and the TMI Yashwanpur hospital, added in FY 2026-2027, is still in ramp-up; management is confident occupancy at both will come in line with the rest of the network (period unspecified).
• FMRI Delhi NCR new block ready and awaiting final approvals — expected within November 2026 (Q3 FY 2026-2027), with all final inspections completed; management said the clinical workforce is ring-fenced via a platform mixing academics, research and practice, with no major attrition despite competitor capacity coming up in Gurgaon.
• Manesar generating positive low double-digit EBITDA — the radiation oncology facility is likely to be commissioned by February 2027 (Q4 FY 2026-2027), with a comprehensive cancer center expected to drive a performance jump from Q1 FY 2027-2028.
• Faridabad, previously a laggard, now touching almost 20% EBITDA (current level, Q2 FY 2026-2027); ~300 doctors added in Q2 FY 2026-2027 across the network.
• Amritsar and Mohali expansions expected to add 500+ beds to the Punjab cluster (period unspecified); management declined to benchmark its growth against listed peers, citing each competitor's own dynamics and geographies.

FY27 Margin "More or Less Intact"; Oncology Price Cap an Unquantified Overhang

• FY 2026-2027 hospital EBITDA margin expected to be flattish — overall margin guidance "more or less intact" despite challenges highlighted on the previous call; the FMRI OC should give some boost to profitability margin.
• Management declined to provide FY 2027-2028 margin guidance — citing noise around drug prices and other factors; it will restrain from guidance and assess how things progress over the forthcoming quarters.
• Recent circular capping prices of 137 cancer/oncology drugs expected to negatively impact profitability — management could not quantify the impact; drugs contribute around one-third of oncology revenue, not all drugs are covered, and certain packages further complicate the assessment; management noted the hospital industry prices at the facility level rather than product-wise, so estimating will take time.
• ESOP disclosed pre-EBITDA because the scheme was rolled out after FY 2026-2027 budgeting — full-year ESOP cost expected at ~Rs.140 Cr (fixed amount); the percentage impact will dilute as the revenue base rises, though management expects the change to not be substantial.
• ARPP growth primarily case-mix driven — more robotic surgeries and complex cases; price increases contribute only ~1.5 percentage points, as pricing capability is very little in this industry.
• FY27 diagnostics revenue growth guided at 12-13% — brand transition impact "largely behind"; management expects mid-teens growth in a few quarters (period unspecified) and thereafter probably targets returning to industry growth (period unspecified).

IHH Stake Intent, Debt Path and Forensic Audit

• Parent IHH has expressed very openly that it wants to increase its stake above 50% — at the current market price, CFO Vivek Goel estimates this would provide additional capital of Rs.10,000 Cr over a period of time (period unspecified).
• Rs.2,200 Cr debt repayment expected in 2 years' time on a steady-state basis (i.e., by FY 2028-2029) — the debt number may go up or down with acquisition capability; inorganic deals are expected to be funded through internal accruals.
• Court-ordered forensic audit progressing — auditors have been appointed and Fortis has submitted the information requisitioned; the court had originally indicated the audit should be completed in 6 months (completion date unspecified), and management is looking forward to getting it behind them.
• Bangalore new unit expected to mirror the 92-bed Nagarbhavi unit — which currently runs 80%+ occupancy — with profitability of ~25% over a period of time (period unspecified), not immediately; ARPP expected below company average but in line with Nagarbhavi at ~Rs.2 crore per bed.